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MicroRNAs (miRNAs) are a group of small non-coding RNA molecules that potentially play a critical role in
tumorigenesis. Increasing evidences indicate that miR-378-5p is dysregulated in numerous human cancers including
colorectal cancer (CRC) which hypothesizes that miR-378-5p may play an important role in tumorigenesis. However,
its role in CRC carcinogenesis remains poorly defined because of lacking target genes information. In the present
study, it was demonstrated that the expression of miR-378-5p was down-regulated in CRC tissues and cell lines as
determined by quantitative reverse transcription-polymerase chain reaction (qRT-PCR). Furthermore, overexpression
of miR-378-5p suppressed cell proliferation, as indicated by CCK-8 assay. Flow cytometric analysis demonstrated that
overexpression of miR-378-5p induced cell cycle arrest and promoted apoptosis in CRC cells. A luciferase reporter
assay indicated that BRAF was a direct target of miR-378-5p. Western blot and qRT-PCR analysis indicated that BRAF
was significantly down-regulated by miR-378-5p in CRC cells. Moreover, miR-378-5p was negatively associated with
BRAF in CRC tissues compared to adjacent non-tumor tissues. These results demonstrate that down-regulation of
miR-378-5p promotes CRC cells growth by targeting BRAF and restoration of their levels is a potentially promising
therapeutic in CRC.
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Colorectal cancer possesses the third highest incidence
of human malignant diseases that account for approxi-
mately 9.4% of worldwide cancer cases. According to the
International Agency for Research on Cancer, about 1
million new cases were detected each year [1]. Much ef-
fort has been made on the study of the biological mech-
anism of CRC and a large number of tumor suppressor
genes and oncogenes have been reported recent years.
However, the molecular mechanisms underlying the
development of CRC are still poorly understood.
miRNAs are defined as endogenous 22 nt RNAs that
play important regulatory roles in animals and plants by
binding to the 3′ untranslated regions (UTRs) of target* Correspondence: zhaorensurgeon@aliyun.com
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unless otherwise stated.mRNAs, causing translation to be blocked and/or mRNA
degradation [2,3]. miRNAs play diverse roles in carcino-
genesis involved in the regulation of tumor proliferation,
invasion, apoptosis and therapy resistance, and may act as
oncogenes or tumor suppressors depending on the target
mRNAs [4-6]. High-throughput technologies such as mi-
croarrays and next generation sequencing have showed
global expression pattern of miRNAs, and quite a number
of miRNAs which are dysregulated in several malignancies
including CRC may act as novel oncogenes or tumor sup-
pressor genes [7,8]. However, the mechanism underlying
CRC tumorigenesis was not clear enough for the lacking
of target genes information.
miR-378-5p is reported dysregulated expressed in sev-
eral malignancies and the function of miR-378-5p is
complicated because it can be oncogenic in glioblast-
oma, breast cancer and non-small cell lung cancer
[9-11] or a tumor suppressor in liver cancer, gastric can-
cer and oral cancer [12-14]. So, identification of cancer-This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Patients’ characteristics of clinical-pathologic
features
Characteristics No. of patients (n = 47) Percent (%)
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their roles in tumorigenesis, and may be important for
finding out novel prognostic and therapeutic targets.
Several studies have reported that miR-378-5p was
significantly down-regulated in CRC [15-18]. However,
the mechanism of miRNA-378-5p in CRC development
is not very clear for poor targeting information.
In the present study, we identify that miR-378-5p is
down-regulated in CRC and can suppress cell prolifera-
tion and induce apoptosis in CRC cells. We prove the
potential tumor suppressor role of miR-378-5p involved
in CRC by identifying one new targeting gene BRAF.
Furthermore, we show that miR-378-5p suppress cell
proliferation and induce apoptosis in CRC cells through
RAS/RAF/MEK/ERK pathway. Our data may suggest a




47 paired CRC and normal tissues were collected from
the Department of General Surgery, Rui Jin Hospital,
Shanghai, China. CRC tissues were obtained from pa-
tients undergoing resection, and adjacent colon tissues
were obtained from distal normal colon tissue of colon
cancers. Informed consent was obtained from each
patients and the study was approved by the Ethics
Committee of Shanghai Jiao Tong University, Shanghai,
China. All tissues were frozened to −80°C for subsequent
experiments. All clinic pathologic and biological data were
available for those patients. Patients’ characteristics of
clinical-pathologic features were listed in Table 1. Add-
itionally, five normal colorectal tissues were obtained from
health people by colonoscopy and exclude colorectal
cancer and polyps.
Cell lines
Human CRC cell lines LoVo, CaCo2, SW1116, SW480,
HCT-116 and human embryonic kidney cell line HEK
293 T were purchased from the Cell Bank of the Chinese
Academy of Sciences (Shanghai, China). The cells were in-
cubated in RPMI1640 (PAN Biotech, Aidenbach, Germany)
with 10% FBS (PAA Laboratories, Pasching, Australia) ex-
cept for HEK 293 T which was incubated in Dulbecco’s
modified Eagle’s medium (DMEM) (PAN Biotech) with
10% FBS (PAA Laboratories). All cells were cultured at
37°C in an atmosphere of 5% CO2.
Quantitative reverse transcription-polymerase chain reaction
Total RNA of 47 paired CRC and normal tissues and cells
were isolated using TRIzol reagent according to the man-
ufacturer’s instructions (Invitrogen, California, USA). The
concentration of all RNAs was measured using spec-
trophotometer (Thermo Fisher Scientific Inc., Waltham,USA) and 1 μg RNA was used for complementary DNA
(cDNA) synthesis using the ReverTra Ace-α- (TOYOBO,
Osaka, Japan) according to the manufacturer’s instruc-
tions. Real-time PCR was performed using the SYBR®
regent (TOYOBO, Kita-ku, Osaka, Japan). The reverse
transcription primer of miR-378-5p was 5′-GTC GTA
TCC AGT GCA GGG TCC GAG GTA TTC GCA CTG
GAT ACG ACA CAC A-3′ (stem-loop primer) and the
amplification primers were as follows: 5′- GC CTC CTG
ACT CCA GGT CC-3′ (sense) and 5′- GTG CAG GGT
CCG AGG T-3′ (antisense). Primers for amplification of
control U6 small nuclear RNA were: 5′-CTC GCT TCG
GCA GCA CA-3′ (sense) and 5′-AAC GCT TCA CGA
ATT TGC GT-3′ (antisense). Primers for BRAF were:
5′-CTT CCC CAG ACC GCG ATT C-3′ (sense) and
5′-CGA CCA CCT CTA TGG TGA CCT-3′ (antisense).
Primers for β-actin were: 5′- AGC AGC ATC GCC CCA
AAG TT-3′ (sense) and 5′-GGG CAC GAA GGC TCA
TCA TT-3′ (antisense). Amplification was performed
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the amplification procedure consisted of 40 cycles (95°C
for 10 seconds, 55°C for 10 seconds, 72°C for 20 seconds)
following an initial denaturation at 95°C for 20 seconds.
The fold change in target mRNA or miRNA expression
was caculated using the 2-ΔΔCt method following normali-
zatoin to β-actin or U6 expression respectively.
RNA interference
BRAF and control siRNA were purchased from Gene-
Pharma company. The sequences of BRAF siRNA was:
5′-GAU GGC GGC GCU GAG CGG UdTdT-3′ (sense)
and 5′-ACC GCU CAG CGC CGC CAU CdTdT-3′
(antisense), negative control siRNA was: 5′-UUC UCC
GAA CGU GUC ACG UdTdT-3′ (sense), 5′-ACG UGA
CAC GUU CGU AGA AdTdT-3′ (antisense). BRAF and
control siRNA were transfected to CRC cell lines SW480
and HCT-116 in a final concentration of 20 nM using
transfection reagent INTERFERin™ (Polyplus, Berkeley,
CA, USA). 48 hours after transfection, cells were harves-
ted for qRT-PCR, cell cycle and cell apoptosis analysis
while western blot analysis was performed after 72 hours.
Western blot analysis
Cells were harvested and lysed using Cell Lysis Buffer
(Cell Signaling Technology, Danvers, MA, USA) and
separated by 10% SDS-polyacrylamide gel (SDS-PAGE)
and blotted to polyvinylidene fluoride (PVDF) mem-
branes (Millipore, Darmstadt, Germany). After blocking
with 5% non-fat milk in TBST (1‰), the PVDF mem-
branes were incubated overnight at 4°C with anti-BRAF
(#9433), anti-phosphorylated (p-)ERK (#9106) (both from
Cell Signaling Technology; both diluted 1:1000) and anti-
c-Myc (sc-40), anti-Bcl2 (sc-7382) (both from Santa Cruz
Biotechnology Inc., California, USA; both diluted 1:1000)
and anti-β-actin (A5441) (Sigma, St Louis, MO, USA),
followed by incubation with a horseradish peroxidase-
conjugated secondary antibody (diluted 1:2000) for 1 hours
at room temperature. Protein bands were detected using
Chemiluminescent Western Blot Scanner (Gene Company,
HongKong, China). The β-actin band intensity served as
the control for BRAF, p-ERK, c-Myc and Bcl2 expression.
Vector construction and luciferase reporter assay
Wild-type (WT) or mutant (Mut) BRAF mRNA fragment
was amplified and cloned into pMIR-Report construct
(Ambion, Austin, TX, USA). Primers used for the BRAF
WT mRNA fragment were: 5′-CCC AAG CTT AGG
ACC TCA GCG AGA AAG GAA GTC AT-3′ (sense)
and 5′-CTA GAC TAG TAC ATC ACC ATG CCA CTT
TCC CTT G-3′ (antisense). Primers used for the BRAF
Mut mRNA fragment were: 5′-CCC AAG CTT ACC
TGG ACA GCC TCA AAG GAA GTC AT-3′ (sense)
and 5′-CTA GAC TAG TAC ATC ACC ATG CCA CTTTCC CTT G-3′ (antisense). The vectors were verified by
direct sequencing. HEK 293 T cells were placed onto
24-well plate and co-transfected with pMIR-BRAF-WT
mRNA reporter plasmids (100 ng) or pMIR-BRAF-Mut
mRNA reporter plasmids (100 ng), pMIR-TK (25 ng)
and miR-378-5p mimics or negative control oligonucle-
otides (50 nM) using jetPEI (Polyplus). After 24 hours,
cells were harvested and the reporter activity was
detected using Dual-luciferase reporter assay system
(Promega, Madison, Wisconsin, USA).Cell proliferation and cell cycle analysis
SW480 and HCT-116 cells were transfected with miR-
378-5p mimics or negative control oligonucleotides
using INTERFERin (Polyplus). Cell proliferation was de-
tected at 24 hours, 48 hours, 72 hours and 96 hours
after transfection using Cell Counting Kit-8 (Dojindo,
Kumamoto, Japan) according to the manufacturer’s in-
structions. In short, 1 × 104 cells were seeded onto 96-
well plates per well in a final volume of 100 μl. At the
indicated time, 10 μl CCK-8 solution was added to each
well and cells were incubated at 37°C for 30 minutes be-
fore detecting the absorbance at 450 nm. For cell cycle
assay, 48 hours after the SW480 and HCT-116 cells were
transfected, the culture medium was changed to RPMI-
1640 without serum for 24 hours, followed by another
6 hours cultured in RPMI-1640 with 10% FBS. Then the
cells were harvested and fixed in 70% ethanol at 4°C
overnight. Cells were stained with propidium iodide (PI)
(Biolegend, California, USA) solution at a final concen-
tration of 50 μg/ml which containing 50 μg/ml RNase A.
Cell cycles were analyzed by flow cytometry (BD LSRII,
San Jose, CA, USA).Cell apoptosis analysis
Cell apoptosis analysis was performed using phycoerythrin
(PE)-annexinV apoptosis detection kit (BD PharMingen,
San Jose, CA, USA). For cell apoptosis analysis, cells were
seeded in 6-well plates at 8 × 105 per well. Seventy-two
hours after transfection, cells in the suspension and that
were adhered were harvested and labeled with AnnexinV
for 15 minutes in dark place. 50 μg/ml PI was added to
each sample before the cell apoptosis distribution was an-
alyzed by flow cytometry (BD LSRII, San Jose, CA, USA).Statistical analysis
All statistical analyses were carried out using the SPSS
16.0 statistical software package. Continuous variables
were expressed as mean ± SEM. Differences between
groups were calculated with Student’s t test. A two-tailed
P value test was used with a P value of < 0.05 considered
statistically significant.
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Expression of miR-378-5p is greatly decreased in CRC
In order to confirm the involvement of miR-378-5p in
CRC, we tested the relative expression level of miR-378-
5p in 47 CRC tissues and corresponding adjacent non-
tumor tissues using qRT-PCR. The results indicated that
miR-378-5p was greatly decreased in CRC tissues com-
pared with adjacent non-tumor tissues (44/47, 93.6%,
p <0.001) (Figure 1A). It was also shown that miR-378-5p
was down-regulated in 5 CRC cell lines, compared with 5
normal colorectal tissues (Figure 1B). These observations
suggest that miR-378-5p may be a tumor suppressor
in CRC.
miR-378-5p inhibits proliferation of CRC cells in vitro
The decreased expression of miR-378-5p in CRC tissues
inspired us to assume miR-378-5p to be a tumor sup-
pressor. The expression level of miR-378-5p was de-
creased in CRC cell lines (Figure 1B) and transfection of
miR-378-5p mimics restored its expression level in both
SW480 and HCT-116 CRC cells (Figure 2A). Then we
investigated the effects of miR-378-5p restoration on
these two cell lines. miR-378-5p mimics and negative
control oligonucleotides were transfected into SW480
and HCT-116 cells and proliferation was tested by CCK-
8 assay. As shown in Figure 2B, proliferation of CRC
cells was suppressed following transfection with miR-
378-5p at 48 hours (19.5%, p <0.05), 72 hours (24.6%,
p <0.05) and 96 hours (29.8%, p <0.01) in SW480 cells
and 48 hours (16.8%, p <0.05), 72 hours (26.1%, p <0.05)
and 96 hours (28.1%, p <0.01) in HCT-116 cells. Taken
together, the results indicate that miR-378-5p inhibits the
proliferation of CRC cells in vitro.
Decreased cell proliferation in cancer cells relates
closely to cell cycle arrest. We then detected whether
cell cycle arrest contributed to the growth inhibition ofFigure 1 miR-378-5p is down-regulated in CRC samples and cell lines. (A)
with adjacent non-tumor tissues. (B) The expression level of miR-378-5p w
*p <0.05, **p <0.01.miR-378-5p transfected cells. The result showed that the
cell cycle was arrested in G1 phase, with 68.9% of miR-
378-5p transfected cells in G0/G1 versus 49.4% of con-
trol cells in SW480 cells. Similar effects of miR-378-5p
were found in HCT-116 cells, with 59.6% of miR-378-5p
transfected cells in G0/G1 versus 47.2% of control
cells (Figure 2C). These results demonstrate that overex-
pression of miR-378-5p inhibits growth of CRC cells by
blocking G1/S transition.
miR-378-5p induces apoptosis of CRC cells in vitro
Next, the ability of miR-378-5p to induce apoptosis in
CRC cell lines was evaluated by co-staining with Annex-
inV and propidium iodide (PI). miR-378-5p mimics and
negative control oligonucleotides were transfected into
SW480 and HCT-116 cells, then apoptosis was tested
by flow cytometric assay. The staining demonstrated
that miR-378-5p could significantly induce apoptosis
in SW480 and HCT-116 cells compared with the negative
control groups with a concomitant decrease in the viable
cell population (Figure 3A,B). This points to a proapop-
totic role of miR-378-5p and suggests that miR-378-5p
affects apoptotic pathways in regulating tumorigenicity.
miR-378-5p directly targets BRAF in CRC cells
In order to investigate the underlying mechanisms of miR-
378-5p in CRC, biological function of CRC pathogenesis-
related genes was further analyzed. In 2013, Aleksandra
Helwak and his colleagues identified more than 18000
high-confidence miRNA-mRNA interactions in HEK 293
cells by CLASH [19]. However, whether these miRNA:
mRNA pairings also exit in CRC cells remaining to be
explored. The CLASH data have showed that 103 genes
were targeted by miR-378-5p. Among these genes, we
focus on gene BRAF, a central component of the RAS/
RAF/MEK/ERK pathway, which is involved in manyExpression of miR-378-5p was down-regulated in 47 CRC compared
as down-regulated in 5 CRC cell lines compared with normal tissues.
Figure 2 miR-378-5p overexpression inhibits CRC cells growth. (A) miR-378-5p mimics restored miR-378-5p expression in both SW480 and HCT-116
cells. (B) Overexpression of miR-378-5p in CRC cells suppressed cell proliferation. (C) Overexpression of miR-378-5p in CRC cells blocked G1/S transition.
*p <0.05, **p <0.01. NC, negative control oligonucleotides.
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other cellular functions [20]. From the CLASH data in
HEK 293 cells, the potential targeting sequence for
miR-378-5p with a calculated energy of −17.1 kcal/mol
is within the protein coding region of BRAF mRNA from
1321 to 1367. To verify the interaction of miR-378-5p
with BRAF, we first performed luciferase reporter assays
in HEK 293 T cells. We cloned the potential targeting
sequence of miR-378-5p into a luciferase reporter vector.
As shown in Figure 4B, transfection of miR-378-5p caused
a significant decrease in luciferase activity in cells trans-
fected with the reporter plasmid with wild-type targeting
sequence of BRAF mRNA but not reporter plasmid withmutant sequence. Then, we explored whether the en-
dogenous BRAF in CRC cells was regulated similarly. The
mRNA and protein level of BRAF in SW480 and HCT-
116 cells was also analyzed after transfection of miR-378-
5p. As shown in Figure 4C and D, The level of BRAF
mRNA and protein was consistently and substantially
down-regulated by miR-378-5p. This result indicates that
miR-378-5p can bind directly to BRAF and inhibits the
expression of BRAF. Knowing BRAF was the target of
miR-378-5p, we tested the expression of BRAF in the 47
CRC and adjacent non-tumor tissues. The results indi-
cated that the expression level of BRAF mRNA was
greatly increased in CRC comparing to adjacent non-
Figure 3 miR-378-5p overexpression induces CRC cells apoptosis. Cell apoptosis was analyzed by FACS analysis. miR-378-5p mimics induced CRC
cells apoptosis in SW480 (A) and HCT-116 (B).
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was inversely related to the expression of miR-378-5p
(Figure 4F).
miR-378-5p inhibits the proliferation and induces apoptosis
of CRC cells via regulation of RAS/RAF/MEK/ERK pathway
Since overexpression of miR-378-5p suppressed prolifer-
ation and induced apoptosis of CRC cells, and given that
BRAF is a direct target of miR-378-5p, we hypothesized
that the inhibitory effect of miR-378-5p on CRC cell
viability might be achieved via targeting BRAF. In order
to investigate this hypothesis, we tested whether RNAi-
mediated reduction in BRAF influence the cell growth
just like miR-378-5p in CRC cells. BRAF is a central
component of the RAS/RAF/MEK/ERK pathway and
most BRAF targeting genes were involved in cell growth
regulation (such as c-Myc) or apoptosis (such as Bcl-2)
[21]. So we investigated effects of miR-378-5p mimics
and BRAF RNAi on RAS/RAF/MEK/ERK pathway in
CRC cells. SW480 and HCT-116 cells were transfected
with miR-378-5p or BRAF siRNA, and protein levels of
RAS/RAF/MEK/ERK pathway were examined b ywestern
blot. The results showed that protein levels of BRAF, p-
ERK, c-Myc and Bcl-2 were consistently down-regulated
by both miR-378-5p mimics and BRAF siRNA (Figure 5A).In addition, treatment of cells with BRAF siRNA markedly
suppressed cell proliferation at 48 hours (26.3%, p <0.05)
and 72 hours (31.3%, p <0.01) in SW480 cells and 48 hours
(22.7%, p <0.05) and 72 hours (29.6%, p <0.01) in HCT-
116 cells (Figure 5B) and significantly induced apoptosis
in SW480 and HCT-116 cells (Figure 5C). These findings
suggest that miR-378-5p suppresses CRC cells growth and
induces apoptosis, at least in part, by targeting BRAF.
Discussion
In this study, we studied the expression profile of miR-
378-5p in CRC. Our results showed that miR-378-5p
was down-regulated in CRC tissues and cell lines which
agreed with the previous studies [15-18]. In addition, we
identified BRAF as a new direct and functional target of
miR-378-5p in CRC cells. Overexpression of miR-378-5p
in CRC cells significantly decreased the proliferation
and induced apoptosis by regulating RAS/RAF/MEK/
ERK pathway.
Since the first miRNA lin-4 has been discovered in 1993,
about 1881 miRNA sequences have been found in human
genome. By attaching to the sequence-complementary
mRNA targets, miRNAs can regulate the expression of
nearly 30% protein coding genes [22,23]. Recently, de-
regulation of miRNAs in cancers and their roles in
Figure 4 miR-378-5p down-regulates BRAF expression in human CRC cells. (A) Wild-type (WT) and mutant (Mut) of putative miR-378-5p targeting
sequences in BRAF mRNA. Mutant sequences were shown in bold type. (B) miR-378-5p mimics inhibited wild-type but not mutant BRAF reporter
activity in HEK 293 T cells. (C) miR-378-5p mimics down-regulated the endogenous BRAF mRNA levels in CRC cells. (D) miR-378-5p down-regulated
the endogenous BRAF protein level in CRC cells. (E) Expression of BRAF was up-regulated in 47 CRC compared to adjacent non-tumor
tissues. (F) A negative Spearman correlation between miR-378-5p and BRAF mRNA was found in 47 CRC tissues. *p <0.05, **p <0.01. NC, negative
control oligonucleotides.
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Michael firstly completed the identification of the miRNA
populations changes of colorectal cancer in 2003 [27].
Now, several deregulated miRNAs in CRC such as miR-
451, miR-34 and miR-135 have been shown to regulate
cell apoptosis, growth, invasion and migration [28-30]. In
this study, we demonstrated that miR-378-5p is dra-
maticly down-regulated in CRC cell lines. This was fur-
ther confirmed by testing the relative expression level of
miR-378-5p in 47 CRC tissues and corresponding adjacent
non-tumor tissues using qRT-PCR. This was consistent
with that miR-378-5p was decreased in CRC and gastric
cancer [12,31]. miR-378-5p was found to be an independ-
ent prognostic factor and could inhibit cell growth and
invasion in CRC by targeting vimentin [32]. However,
the role of miR-378-5p in CRC is not well known for
the limitation of target gene information. Our resultsdemonstrated that BRAF was another direct target gene
of miR-378-5p in CRC cells. Overexpression of miR-
378-5p in CRC cells decreased both mRNA and protein
level of BRAF in CRC cells. Our results also showed
that miR-378-5p was negatively correlated with BRAF
mRNA in CRC tissues. In addition, Overexpression of
miR-378-5p in CRC cells significantly decreased the pro-
liferation and induced apoptosis by regulating RAS/RAF/
MEK/ERK pathway. Interestingly, the function of miR-
378-5p is complicated because it can be oncogenic in glio-
blastoma, breast cancer and renal cell carcinoma [9,10,33]
or a tumor suppressor in liver cancer, colorectal cancer,
gastric cancer and oral cancer [12,13,31]. Why miR-378-
5p functions so differently in different kinds of tumors?
This may owe to the differences of the tumor micro-
environment, including the external stimula, the inflam-
mational environment or the stroma cells, which lead
Figure 5 Knockdown of BRAF significantly inhibits cell proliferation and induces apoptosis in CRC cells. (A) Down-regulation of BRAF by miR-378-5p
mimics and knockdown of BRAF by siRNA significantly inhibited RAS/RAF/MEK/ERK pathway in CRC cells. (B) Knockdown of BRAF by siRNA significantly
inhibited proliferation in CRC cells. (C) Knockdown of BRAF by siRNA significantly induced apoptosis in CRC cells. **p <0.01. NC, negative control.
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ism needs further study.
BRAF is a member of the Raf family that are serine/
threonine kinases and plays an important role in cell
proliferation, differentiation and apoptosis by participat-
ing in the mitogen-activated protein kinase (MAPK)/
extracellular signal-regulated kinase (ERK) signaling path-
way [34-36]. It has been reported that 59% of melanomas,
18% of CRCs, 11% of gliomas, and 4% of lung adenocar-
cinomas and ovarian carcinomas contain BRAF muta-
tions, which result in persistent activation of the MAPK/
ERK pathway that leads to sustained proliferative signaling
[37]. However, recent studies show that metastases of
CRC rarely contain BRAF mutation with BRAF wild-type
primary tumours [38]. The relationship between the pres-
ence of BRAF mutation and the effect of anti-EGFR
monoclonal antibodies is argumentative.Some studies
show that patients with BRAF mutation may have a poor
reaction to vemurafenib which is an anti-EGFR mono-
clonal antibodies [39]. On the contrary,Troiani thought
BRAF mutation had no necessary connection with thesensitivity to selumetinib [40]. Increasing studies revealed
that deregulation of miRNAs was responsible for abnor-
mal expression of human BRAF in many cancers [41].
Several miRNA were reported as regulators of BRAF in
different cancers such as miR-524-5p in melanoma, miR-
143 and miR-145 in CRC [42,43]. In this study, BRAF was
identified to be directly targeted and regulated by miR-
378-5p in CRC cells. Our results agreed with the view-
point that a single mRNA molecule can been regulated by
multiple miRNA genes in different cells [44-46].
In conclusion, our study demonstrates that the expres-
sion of miR-378-5p is decreased in CRC. miR-378-5p
can inhibit proliferation of CRC cells and induce CRC
cells apoptosis by directly suppressing the expression
of BRAF. All of the above indicate that miR-378-5p is
served as an anti-oncogene in CRC.
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